Peer Review
Cancer Imaging
ISSN 1470-7330
Search site with:PicoSearch


Content
Current Issue
Archive
Related Journals / Articles
Information
Aims and Scope
Editors and Board
Editorial Policy
Instructions for Authors
Copyright Transfer Form
Subscription Information
Advertising
Society
Aims
Membership
Annual Meeting
Communications
Bulletin Board
Send Email to ICIS
e-Med
Visit e-Med Web Site
Journals
Purchase
“To Promote Education in Cancer Imaging in the Multidisciplinary Management of Malignancy”

Home > Articles

Role of contrast-enhanced color Doppler ultrasonography and dynamic flow in the evaluation of hepatic tumors treated with radiofrequency

Abstract

The contribution of contrast-enhanced color Doppler ultrasonography (CDUS) and dynamic flow (DF) (Toshiba) in the evaluation following treatment of hepatic tumors with radiofrequency (RF) is discussed. Twenty-seven patients with 34 hepatic tumors were included in this prospective study. The treated tumors measured 10--58 mm in diameter (mean diameter 29 mm). Two tumors were treated twice and one three times, comprising a total of 38 target lesions treated with RF and evaluated by 127 contrast-enhanced CDUS. The results of CDUS follow-up were compared to those of the dynamic MRI at 2 months, 4 months, 6 months and 1 year. Before RF, the injection of Levovist raised the number of vascularized lesions seen with unenhanced Doppler from 44% to 79%. All the non-vascularized lesions were metastases. Twenty-four hours after RF, four tumors presented an enhancement with Levovist, in which two were insufficiently treated lesions. Twenty-one treated tumors have been followed-up jointly by CDUS and MRI at the same time at 2 months, 20 at 4 months, 12 at 6 months and nine at 1 year. Compared to the MRI and the evolution, the CDUS presented a sensitivity of 100% and a specificity of 90% for the detection of progressive recurrence. The preliminary results show that the CDUS is useful to confirm the absence of detectable vascularity after treatment with RF ablation, whereas the presence of enhancement must be confirmed by MRI.

Author

N Lassau, M Lamuraglia, I Chawi, T Smayra, C Dromain, S Koscielny, T de Baere, J Leclere and A Roche

Contact Details

Corresponding address:
Nathalie Lassau,
Institut Gustave Roussy,
39 rue Camille Demoulins,
94805 Villejuif Cedex,
France

Reference

ICIS Cancer Imaging Volume 5 Issue 1
DOI: 10.1102/1470-7330.2005.0011

Date Posted

25 May 2005


Print PDF

Size

1.26 MB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):

5 seconds

ADSL 512Kb/s (Broadband):

20 seconds

64 Kb/s (ISDN):

2 minutes 40 seconds

33.3 Kb/s (Typical Modem):

5 minutes 9 seconds

Screen PDF

Size

555.44 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):

2 seconds

ADSL 512Kb/s (Broadband):

8 seconds

64 Kb/s (ISDN):

1 minute 9 seconds

33.3 Kb/s (Typical Modem):

2 minutes 13 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.

© 2000-2009 International Cancer Imaging Society